928D2F99-A86B-47CA-A961-A8CAE7B44E78
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6.3731931668856765
- age_years
- 36
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.579
- INTERFERON_GAMMA_RESPONSE+0.565
- INTERFERON_ALPHA_RESPONSE+0.533
- NOTCH_SIGNALING+0.517
- IL6_JAK_STAT3_SIGNALING+0.516
- INFLAMMATORY_RESPONSE+0.515
- TNFA_SIGNALING_VIA_NFKB+0.508
- TGF_BETA_SIGNALING+0.493
- MYC_TARGETS_V1+0.460
- PROTEIN_SECRETION+0.431
Top 10 suppressed
- KRAS_SIGNALING_DN-0.352
- SPERMATOGENESIS-0.339
- MYOGENESIS-0.209
- PANCREAS_BETA_CELLS-0.188
- APICAL_SURFACE-0.095
- HEDGEHOG_SIGNALING+0.001
- BILE_ACID_METABOLISM+0.034
- APICAL_JUNCTION+0.041
- GLYCOLYSIS+0.059
- CHOLESTEROL_HOMEOSTASIS+0.071
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9ECB653A-A04F-457C-92FC-D13424511A47 | — | — | 0.956 |
| 2 | 165395C6-1028-49DF-B15D-4D8064D00995 | — | — | 0.951 |
| 3 | SRR934921 | — | — | 0.943 |
| 4 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.943 |
| 5 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.941 |
| 6 | B583566B-A014-417A-A973-41204DC35ECF | — | — | 0.939 |
| 7 | SRR934807 | — | — | 0.937 |
| 8 | 1B1E827B-A98A-465E-AC6F-448C076E829D | — | — | 0.936 |
| 9 | 385ECC71-2BF4-4E14-B2CC-8423E79BDEBE | — | — | 0.936 |
| 10 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.936 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.579 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.565 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.533 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.517 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.516 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.515 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.508 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.493 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.431 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.420 | Idelalisib | — uncovered |
| COMPLEMENT | 0.401 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.378 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.374 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.353 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.349 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.319 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.312 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.297 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.293 | Inavolisib | — uncovered |